WebSep 11, 2024 · Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells. ABOUT IMMUNOGEN WebMay 16, 2024 · The Company conducted the phase 3 FORWARD I trial in which 366 patients were randomized 2:1 to receive either mirvetuximab soravtansine or the physician’s choice of single-agent chemotherapy ...
A Study of Mirvetuximab Soravtansine vs. Investigator
WebFeb 18, 2024 · This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. Detailed Description: 136 patients will be randomized into the follow-ing two treatment arms as specified below: WebFuture Medicine: “FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer,” “A review of mirvetuximab … ian grey gm
ImmunoGen
WebMay 20, 2016 · Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC), comprising a FRα-binding antibody linked to the tubulin-disrupting maytansinoid DM4, that has shown single agent clinical activity and favorable safety in an ongoing phase 1 trial (NCT01609556). WebOct 28, 2024 · Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. WebOct 13, 2024 · Preplanned and exploratory analyses of PRO data collected during the FORWARD-1 trial were used to determine differences between treatment with mirvetuximab soravtansine and chemotherapy,... ian grey discarded things